Posted from: Thursday, September 18, 2014 - 02:46 PM - Present

Incivek to be Discontinued by Vertex

Recently Vertex Pharmaceuticals announced that it would be discontinuing its Hepatitis C medication Incivek by October 16, 2014. 

Incivek was part of a interferon-based drug regimen used in the treatment of genotype 1 chronic hepatitis C infections in adults with compensated liver disease. The decision made by Vertex was based on the decreased market demand in conjunction with newly available Hepatitis C therapies. 

Vertex is asking that physicians not to start new patients on Incivek but plans to provide enough supply for patients currently taking Incivek to complete their treatment regimen. 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Friday, May 19, 2017 - 03:55 AM.